Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

AstraZeneca's China boss says drugmaker will seek to "love the Communist Party"

Published 05/19/2023, 05:33 AM
Updated 05/19/2023, 05:36 AM
© Reuters. FILE PHOTO: The logo of the British pharmaceutical company AstraZeneca is seen at the company's  China Commercial Innovation Centre (CCIC) in Wuxi, Jiangsu province, China, September 15, 2018.  REUTERS/Adam Jourdan

By Joe Cash and Brenda Goh

BEIJING (Reuters) - Global drugmaker AstraZeneca (NASDAQ:AZN) will seek to be a patriotic company in China that "loves the Communist Party", its China president said at an event on Friday.

Wang Lei, who is also the company's global executive vice president, made the comments at an event in the eastern city of Wuxi which the firm organised to celebrate its 30th year in China, according to a person familiar with the matter and photos shared with Reuters.

While many local companies have in recent years publicly pledged allegiance to the ruling Chinese Communist Party as President Xi Jinping strengthened the party's role throughout Chinese society and its economy, such messaging is still unusual from foreign companies.

"Build a local, transnational company that loves the Communist Party and loves the country," Wang said in his presentation to an audience of a few hundred participants, with the words flashed across the screen behind him.

AstraZeneca declined to comment.

The comments come as AstraZeneca has been increasing its bets in China with a $450 million investment to build a factory to make inhalers. Last year, China accounted for 13% of AstraZeneca's total sales and the company is China's biggest drugmaker.

Since China started reopening its borders earlier this year following the end of its three-year zero-COVID policy, many heads of foreign firms include AstraZeneca's CEO Pascal Soriot and Apple (NASDAQ:AAPL)'s Tim Cook have paid the country a visit to stress their commitment to China.

But a recent crackdown on consulting and due diligence firms by Chinese authorities is sending jitters across foreign companies, many of who had used such consultancies to conduct research on the market and prospective deals.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.